Trial Profile
A phase III study of TAK-536 (long-term use study)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 May 2016
Price :
$35
*
At a glance
- Drugs Azilsartan (Primary)
- Indications Essential hypertension
- Focus Adverse reactions
- Sponsors Takeda
- 24 May 2016 New trial record